Company intelligence / Profile preview
ChiRhoClin, Inc.
- Ownership
- Private
- Development stage
- Commercial
Overview
ChiRhoClin specializes in orphan drug development for gastrointestinal and radiological applications. Its lead product, ChiRhoStim® (Human Secretin for Injection), has FDA approval for pancreatic function testing, facilitating cannulation during ERCP procedures, gastrinoma testing, and supporting imaging diagnostics. The company collaborates with hospitals and universities to advance pancreatic disease research. Clinical results have established the utility of ChiRhoStim® in improving diagnostic accuracy and procedural success rates in relevant indications.
- Therapeutic areas
- GastroenterologyOncology
- Modalities
- Synthetic peptides (notably secretin)
- Industry
- Biotech
Drug pipeline
3 assets2 more assets in the full pipeline.
Request access →Partnerships
Beyond the preview
Go deeper on ChiRhoClin, Inc..
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ChiRhoClin, Inc..